Siloton secures £470k in seed funding led by Quantum Exponential Group and Evenlode Impact to develop diagnostic imaging technology
The seed round was led by Quantum Exponential Group and Evenlode Impact to support diagnostic imaging development.
Siloton is a Bristol-based health technology start-up developing miniature optical coherence tomography chips for eye imaging. The firm aims to make retinal disease monitoring more accessible for patients and healthcare providers.
Siloton has secured approximately £470k in a seed investment round led by Quantum Exponential Group and Evenlode Impact. The funding also drew participation from several angel investors including Michael Tibbets, Zbigniew Łukasiak, Nick Holzherr, Grzegorz Jakacki, Priyanka Mandal, and Darshak Shah.
The proceeds from the round will be directed towards furthering the development of the company's diagnostic imaging technology. Siloton intends to reach key technology milestones and establish partnerships with major stakeholders across the global supply chain as it advances its photonic integrated circuit systems.
From the founder
"The closing of Siloton’s first round of investment represents a new chapter in the company’s history. We have a strong management team with world-leading technical know-how. This knowledge is complemented by the considerable expertise contained within our investor base; including clinical, sector, and commercial experts. We are all deeply excited to begin working together and building a compelling product for patients with age-related macular degeneration"
Alasdair Price
CEO at Siloton
Use of funds
- 01Continue product development
Investors
Quantum Exponential Group
Evenlode Impact
Michael Tibbets
Zbigniew Łukasiak
Nick Holzherr
Grzegorz Jakacki
Priyanka Mandal
Darshak Shah
Categories
About the company
Siloton
Siloton develops miniature optical coherence tomography chips to improve eye imaging and retinal disease monitoring.